Healthcare

Drug and Gene Delivery Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 to 2030

Share This Article

According to Report Study, the drug and gene delivery devices market size is expected to reach over USD 815 billion by 2030 from at USD 410 billion in 2021, expanding growth at a CAGR of 7.2% from 2021 to 2030.

The Latest Research Study on Drug and Gene Delivery Devices Market Size By Delivery Type: Oral, Ocular, Inhalation, Nasal, Injectable, Transdermal, and Topical; By Method: In Situ and Ex Vivo; By Vector: Viral and Non-Viral – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030.

Get the sample pages of report@ https://www.precedenceresearch.com/sample/1388

What are the Growth Factors?

The global drug and gene delivery devices market is primarily driven by the rising prevalence of various chronic diseases such as cancer, diabetes, and cardiovascular diseases among the global population. The rapid growth of the biopharmaceuticals industry resulted in the development of various therapeutics and gene therapeutics that can effectively treat various chronic diseases and genetic diseases. The rising adoption of such drugs among the population is boosting the growth of the global drug and gene delivery devices market.

Furthermore, the rising investments by the market players in the research and development of the drug delivery systems are fostering the market growth. The technological advancements are providing easy to use and convenient administration of drugs through various roots, which is expected to drive the drug and gene delivery devices market across the globe.

Report Highlights

  • North America dominated the global drug and gene delivery devices market in 2020. The increased number of patients suffering from chronic diseases in the US has fostered the market growth in the region.
  • Asia Pacific is estimated to be the fastest-growing market during the forecast period. The presence of several top biopharmaceutical companies in the nations like India, China, and South Korea is propelling the market growth.
  • Based on the delivery type, the injectable is estimated to be the most opportunistic segment during the forecast period. This can be attributed to the development and rising popularity of various injectable such as pen-injectors, self-injectors, and auto-injectors that emerged as a result of the technological advancements in the market.
  • Based on the method, the in situ segment dominated the market in 2020. This can be attributed to the certain advantages associated with the in situ method such as low complication in fabrication and ease of drug administration. Moreover, the majority of the drugs that are currently used follows the in situ method.
  • Based on the vector, the viral vector segment dominated the market in 2020. This is due to the increased usage of the viral vectors for the majority of the clinical trials. Moreover, the rising prevalence of genetic disorders and chronic diseases among the global population is further fueling the segment growth.

Ask here for customization study@ https://www.precedenceresearch.com/customization/1388

OBJECTIVES OF THE STUDY

  • To analyze and forecast the Drug and Gene Delivery Devices market, in terms of value and volume
  • To provide information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
  • To define, segment, and project the size of the global Drug and Gene Delivery Devices market on the product type, end-use and other segments
  • To project the size of the market, with respect to five main regions, namely, North America, Europe, Asia Pacific (APAC), the Middle East & Africa, and South America, with their key countries
  • To strategically analyze micromarkets with respect to individual growth trends, growth prospects, and their contribution to the total market
  • To analyze opportunities in the market for stakeholders and provide a competitive landscape of the market leaders
  • To strategically profile key players and comprehensively analyze their core competencies
  • To track and analyze research & development (R&D) and competitive developments such as joint ventures, mergers & acquisitions, and new product developments in the Drug and Gene Delivery Devices market

Research Methodology

  • Market estimate for 2021
  • Average selling price (ASP) per region for specific product type
  • Filtrations and assortment of gathered data, to estimate the base year (2021) market size for the country
  • Gathering data from company websites, annual reports, white papers, financial reports, broker reports, investor presentations, and SEC filings
  • National government documents, statistical databases
  • News articles, press releases, and webcasts specific to companies operating in the market
  • Country wise analysis through internal and external proprietary databases, and relevant patent and regulatory databases
  • Determination of market penetration by country

Major Players Covered in this Report

The updated market research report on Drug and Gene Delivery Devices market allows the buyers and manufacturers to stay updated with the current market trends, ongoing happenings, and a clear picture on the market scenario. List of key players included in the research report will help the market vendors to know their market position and plan more operational strategies to gain topmost position among other players. The report offers crucial company information on each market player, such as company profile, financial information, and recently adopted growth strategies. This will help other existing players and the new entrants to plan strategies and establish their presence in the market.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

  • Company Overview
  • Company Market Share/Positioning Analysis
  • Product Offerings
  • Financial Performance
  • Recent Initiatives
  • Key Strategies Adopted by Players
  • Vendor Landscape
  • List of Suppliers
  • List of Buyers
The major players operating in the drug and gene delivery devices market are Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, Uniqure NV.

Segments Covered in the Report

By Delivery Type

  • Oral
  • Ocular
  • Inhalation
  • Nasal
  • Injectable
  • Transdermal
  • Topical

By Method

  • In Situ
  • Ex Vivo

By Vector

  • Viral Vector
  • Non-Viral Vector

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug and Gene Delivery Devices Market 

5.1. COVID-19 Landscape: Drug and Gene Delivery Devices Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug and Gene Delivery Devices Market, By Delivery

8.1. Drug and Gene Delivery Devices Market, by Delivery Type, 2021-2030

8.1.1. Oral

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Ocular

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Inhalation

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Nasal

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Injectable

8.1.5.1. Market Revenue and Forecast (2019-2030)

8.1.6. Transdermal

8.1.6.1. Market Revenue and Forecast (2019-2030)

8.1.7. Topical

8.1.7.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Drug and Gene Delivery Devices Market, By Method

9.1. Drug and Gene Delivery Devices Market, by Method, 2021-2030

9.1.1. In Situ

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Ex Vivo

9.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Drug and Gene Delivery Devices Market, By Vector 

10.1. Drug and Gene Delivery Devices Market, by Vector, 2021-2030

10.1.1. Viral Vector

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Non-Viral Vector

10.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Drug and Gene Delivery Devices Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.1.2. Market Revenue and Forecast, by Method (2019-2030)

11.1.3. Market Revenue and Forecast, by Vector (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Method (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Vector (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Method (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Vector (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.2.2. Market Revenue and Forecast, by Method (2019-2030)

11.2.3. Market Revenue and Forecast, by Vector (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Method (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Vector (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Method (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Vector (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Method (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Vector (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Method (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Vector (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.3.2. Market Revenue and Forecast, by Method (2019-2030)

11.3.3. Market Revenue and Forecast, by Vector (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Method (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Vector (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Method (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Vector (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Method (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Vector (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Method (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Vector (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.4.2. Market Revenue and Forecast, by Method (2019-2030)

11.4.3. Market Revenue and Forecast, by Vector (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Method (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Vector (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Method (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Vector (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Method (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Vector (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Method (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Vector (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.5.2. Market Revenue and Forecast, by Method (2019-2030)

11.5.3. Market Revenue and Forecast, by Vector (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Method (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Vector (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Delivery (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Method (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Vector (2019-2030)

Chapter 12. Company Profiles

12.1. Pfizer, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. F. Hoffmann-La Roche Ltd

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Johnson and Johnson Private Ltd

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Novartis AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bayer AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Becton, Dickinson and Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Uniqure NV

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Buy this Research Report study@ https://www.precedenceresearch.com/checkout/1388

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

https://twitter.com/Precedence_R

Steve Robber

My name is Steve Robber, I’m the Owner of Market Stats News. Steve has served in many positions at various organizations for the past seven years. Currently he is an Author at Finance.Yahoo. Contact us for a free news publication, we look forward to speaking with you!

Related Articles

Back to top button